Multi-plex cytokine profiling differentiates autoimmune diseases, identifies high-risk uncategorized patients

The accurate and early diagnosis of systemic autoimmune diseases remains a significant clinical challenge, often relying on the manifestation of late-stage physical symptoms. This delay can impede timely intervention and lead to suboptimal patient outcomes. Current diagnostic methods frequently lack the precision needed to differentiate between clinically similar pathologies or to categorize patients with undifferentiated autoimmune diseases. Exploring molecular biomarkers, such as serum cytokine profiles, offers a promising avenue to provide earlier, more objective diagnostic clarity by revealing underlying immunological signatures that precede overt clinical criteria.

This cross-sectional pilot study analyzed serum samples from 60 patients across five distinct groups: Rheumatoid Arthritis (n=18), Multiple Sclerosis (n=12), Psoriatic Arthritis (n=12), Allergy (n=6), and Uncategorized (n=12). Researchers utilized a 13-plex cytokine array (Aimplex, USA) to quantify levels of pro-inflammatory (Th1/Th17), regulatory (Th2), and innate cytokines in pg/mL. The primary endpoint was to identify distinct molecular signatures that could differentiate between these cohorts and to assess the diagnostic utility of cytokine profiling for uncategorized patients.

Distinct molecular signatures were successfully identified for each cohort, demonstrating statistically significant variations across groups (all p < 0.05). Multiple Sclerosis patients exhibited significant Th17 polarization, characterized by elevated IL-17A levels. In contrast, Rheumatoid Arthritis was primarily defined by the activation of the IL-6/TNF-α axis. The Uncategorized group presented a median IL-6 of 8.5 pg/mL with a striking interquartile range (IQR) of 2.0-439.0 pg/mL, indicating the presence of high-intensity inflammatory "explosions" in these treatment-naïve individuals. Conversely, the Allergy group was distinguished by significantly elevated regulatory IL-10 (median: 6.83 pg/mL) and minimal pro-inflammatory signaling. Discriminant analysis proved highly effective, successfully clustering 85% of the uncategorized cases into defined immunological profiles based on these unique cytokine patterns. These findings underscore the ability of multi-plex cytokine profiling to differentiate between clinically similar pathologies.

The extreme cytokine range observed in uncategorized patients suggests that molecular screening can identify high-risk individuals before formal clinical criteria for a specific autoimmune disease are met.